The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study

European Journal of Endocrinology

Volumn 170, Issue 2, 2014, Pages 193-200

  Stanworth, R D ^a   Akhtar, S ^b   Channer, K S ^c   Jones, T H ^d,e  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^d BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893691406     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0703     Document Type: Article

References (22)

1. Chamberlain NL, Driver ED & Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 1994 22 3181-3186. (doi:10.1093/nar/22.15.3181)
2. Beilin J, Ball EM, Favaloro JM & Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. Journal of Molecular Endocrinology 2000 25 85-96. (doi:10.1677/jme.0.0250085)
3. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J & Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Research 2000 60 5111-5116.
4. Zeegers MP, Kiemeney LA, Nieder AM & Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiology, Biomarkers & Prevention 2004 13 1765-1771.
5. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, Hennekens CH & Kantoff PW. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate 1999 39 130-134. (doi:10.1002/(SICI)1097-0045(19990501)39:2!130::AID-PROS8O3.0.CO;2- #)
6. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O & Ogawa O. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1999 41 253-257. (doi:10.1002/(SICI)1097-0045(19991201)41:4!253::AID-PROS5O3.0.CO;2-9)
7. Krithivas K, Yurgalevitch SM, Mohr BA, Wilcox CJ, Batter SJ, Brown M, Longcope C, McKinlay JB & Kantoff PW. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. Journal of Endocrinology 1999 162 137-142. (doi:10.1677/joe.0.1620137)
8. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M & Nieschlag E. Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. Journal of Clinical Endocrinology and Metabolism 2001 86 2585-2590. (doi:10.1210/jc.86.6.2585)
9. Mifsud A, Sim CK, Boettger-Tong H, Moreira S, Lamb DJ, Lipshultz LI & Yong EL. Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of risk formale infertility. Fertility and Sterility 2001 75 275-281. (doi:10.1016/S0015-0282(00)01693-9)
10. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clinical Endocrinology 2001 55 649-657. (doi:10.1046/j.1365-2265.2001.01391.x)
11. Harkonen K, Huhtaniemi I, Makinen J, Hubler D, Irjala K, Koskenvuo M, Oettel M, Raitakari O, Saad F & Pollanen P. The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. International Journal of Andrology 2003 26 187-194. (doi:10.1046/j.1365-2605.2003. 00415.x)
12. Zitzmann M, Gromoll J, von Eckardstein A & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003 46 31-39.
13. Stanworth RD, Kapoor D, Channer KS & Jones TH. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology 2008 159 739-746. (doi:10.1530/EJE-08-0266)
14. Zitzmann M, Depenbusch M, Gromoll J & Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. Journal of Clinical Endocrinology and Metabolism 2003 88 2049-2054. (doi:10.1210/jc.2002-021947)
15. ZitzmannM& Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2007 92 3844-3853. (doi:10.1210/jc.2007-0620)
16. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011 34 828-837. (doi:10.2337/dc10-1233)
17. Vermeulen A, Rubens R & Verdonck L. Testosterone secretion and metabolism in male senescence. Journal of Clinical Endocrinology and Metabolism 1972 34 730-735. (doi:10.1210/jcem-34-4-730)
18. Mohlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J, Pfeiffer AF & Schofl C. Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. European Journal of Endocrinology 2011 164 1013-1018. (doi:10.1530/EJE-10-1022)
19. Kapoor D, Goodwin E, Channer KS & Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006 154 899-906. (doi:10.1530/eje.1.02166)
20. Boyanov MA, Boneva Z & Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003 6 1-7.
21. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A & Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-Aged men: a meta-Analysis. Clinical Endocrinology 2005 63 280-293. (doi:10.1111/j.1365-2265.2005.02339.x)
22. Stanworth RD, Kapoor D, Channer KS & Jones TH. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clinical Endocrinology 2011 74 624-630. (doi:10.1111/j.1365-2265.2011.03969.x)